Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
March 05, 2007 10:55 ET
|
Samaritan Pharmaceuticals, Inc.
Enters Service Agreement With Advinus Therapeutics, India to Validate
Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol
Strategy is to Bolster Caprospinol Alzheimer's Data...
Samaritan Pharma Completes Acquisition of Metastatin Pharmaceuticals
March 01, 2007 09:56 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, March 1, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announced today that the company has closed its acquisition of...
Shire plc Signs Marketing Agreement With Samaritan Pharma
February 26, 2007 10:24 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Feb. 26, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, is pleased to announce it has signed a marketing and distribution agreement,...
Samaritan Pharma Files Patent to Protect SP-04 as Bioterrorism Nerve Gas Antidote
February 22, 2007 09:53 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Feb. 22, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce it has filed a patent application to protect SP-04 as a...
Samaritan Pharma Aims At SP-6300 as New Innovative Treatment for Cushing's Syndrome
February 06, 2007 12:05 ET
|
Samaritan Pharmaceuticals, Inc.
Files New Patent Application for SP-6300 Making Use
of SP-01A's Phase II Study Data
Drug SP-01A (HIV), SP-6300 (Cushing's) Demonstrates a Statistically
...
Samaritan Pharma Requests Hearing Before AMEX's Listing Qualifications Panel to Appeal Non-Acceptance of Company's Compliance Plan
February 02, 2007 18:01 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Feb. 2, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announces it has requested a hearing before the AMEX's listing qualifications...
Samaritan Pharma's SP-10 Hip On Hep C
January 25, 2007 12:33 ET
|
Samaritan Pharmaceuticals, Inc.
* National Institutes of Allergy and Infectious Diseases (NIAID)
Finds Significant Antiviral Activity With Entry Inhibitor SP-10
for Hepatitis C Virus (HCV)
* "Oral" Antiviral Entry...
Breath of Life Product In-Licensed to Samaritan Pharma
January 22, 2007 10:54 ET
|
Samaritan Pharmaceuticals, Inc.
* ONY's Neonatal U.S. Approved Drug Infasurf to Treat Respiratory
Distress Syndrome in Premature Infants In-Licensed
* Marketing and Sales Rights Granted for Turkey, Serbia, Bosnia,
...
Samaritan Pharma In-Licenses Rights to Promote and Sell Six of Molteni's Prescription Drugs for Pain, Drug Addiction and Anesthesia in Greece and Cyprus
January 16, 2007 10:33 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Jan. 16, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce that it has signed an exclusive license with Molteni...
FDA Grants IND to Samaritan's Novel Plaque Clearing Alzheimer's Drug and Requests Additional Information Be Provided Before Starting Its Proposed Phase I Trial
December 07, 2006 10:15 ET
|
Samaritan Pharmaceuticals, Inc.
LAS VEGAS, Dec. 7, 2006 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced that the U.S. Food and Drug Administration (FDA) has completed its...